Post Analysis

Claims Found

• Ursula von der Leyen, EU Commission President, approved a €320 million grant from the EU's COVID recovery fund for a gene therapy research center in Padua, Italy.

  30%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Assessment

  What checks out:

  • There is a real €320 million funding programme for a national gene-therapy/RNA research initiative whose hub/coordinating centre is based at the University of Padova (Padua)¹²³.
  • The money comes from the EU's post-pandemic recovery fund — Italy's National Recovery and Resilience Plan (NRRP), financed by NextGenerationEU⁴³¹.

  What does not check out — the central attribution:

  • The claim that Ursula von der Leyen "approved" the grant is misleading. Reporting on the controversy states plainly that "the €320 million was not a cheque written by Ursula von der Leyen to a research centre… It formed part of Italy's National Recovery and Resilience Plan," and that "there is no evidence that Ursula von der Leyen personally directed the money to the project"⁴.
  • Independent fact-checking of the viral version concludes the accusation "goes beyond the available evidence": the money "was not personally awarded by Ursula von der Leyen," and the project was selected and administered by Italy, not by the Commission President personally⁵.
  • The €320 million funded a nationwide network (dozens of universities, public research bodies and private partners), not a single Padua entity⁵³².
  • On the underlying conflict-of-interest question, the EU transparency commissioner found no violation of EU conflict-of-interest rules regarding Heiko von der Leyen's role⁶⁵.

  Reasoning:

  • The claim mixes true elements (the €320M sum, the EU recovery-fund origin, the Padua-linked gene-therapy centre) with a false/misleading core — that von der Leyen personally approved the grant. Sources consistently describe this personal-approval framing as unsupported. The kernel of truth (EU/NRRP money reaching the centre) is real, but the claim as worded misattributes the decision, so it is largely misleading rather than accurate.

  Overall validity: 30%

  1. Will Italy’s bet on advanced therapies pay off? | Nature Italy
  2. The Future Is Now: Italy’s National Center enters a new phase for gene therapies and RNA-based medicines - RNA Genetherapy
  3. Gene therapies and RNA drugs, Italia now has a research network - Il Sole 24 ORE
  4. Ursula von der Leyen Has a Transparency Problem - https://eutoday.net
  5. Instagram
  6. EU transparency commissioner: No conflict of interest for Ursula von der Leyen’s husband – POLITICO
• Ursula von der Leyen flew to Rome to personally approve Italy's EU COVID recovery fund money.

  85%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Reasoning

  • The claim's core event is real: on 22 June 2021, European Commission President Ursula von der Leyen travelled to Rome and, at a joint press conference with Italian PM Mario Draghi, announced the Commission's formal approval of Italy's pandemic recovery plan.¹²
  • The Commission's own page confirms "Commission president Ursula von der Leyen presents the Commission's assessment of the original plan to former Prime Minister Draghi in Rome on 22 June 2021."³
  • The amount was the EU's largest allocation: €191.5 billion (€68.9bn grants + €122.6bn loans) under NextGenerationEU.⁴¹²
  • She was on a multi-city tour that day (Rome, Berlin, Riga) to launch the recovery fund, so Rome was one stop on that tour rather than a single-purpose trip.⁵²
  • Minor nuance: the endorsement was formally a decision of the College of Commissioners (with final Council sign-off in July 2021), so "personally approve" slightly overstates her individual role — but the trip, the approval, and her role in announcing it are all accurate.³¹

  Overall validity: 85%

  1. EU approves 191.5 billion euros in recovery funds for Italy | PBS News
  2. EU endorses 3 member states' post-COVID recovery plans
  3. Italy’s recovery and resilience plan - Reforms and Investments
  4. EU endorses 3 member states' post-COVID recovery plans - Chinadaily.com.cn
  5. EU launches coronavirus stimulus program
• Heiko von der Leyen is a medical director at Orgenesis, an American biotech company.

  95%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Reasoning:

  • Heiko von der Leyen is listed as "Medical Director" on Orgenesis's own management team page¹, and his LinkedIn profile confirms the role "Medical Director at Orgenesis Inc. (Sep 2020 to present)"².
  • Wikipedia states that "since December 2020, he is Medical Director of the company Orgenesis, which specialises in cell and gene therapies"³.
  • Orgenesis is described as the "American biotechnology company Orgenesis," which focuses on cell and gene therapy research, with Heiko holding the position since 2020⁴; another source calls it a "U.S.-based biotechnology company"⁵.
  • Multiple independent sources (company site, LinkedIn, Wikipedia, business databases, and a fact-checking outlet) consistently confirm both the role and the company's American identity.

  Overall validity: 95%

  1. Orgenesis | Team
  2. Heiko von der Leyen – Orgenesis Inc.
  3. Heiko von der Leyen - Wikipedia
  4. It Is False That Ursula Von Der Leyen’s Husband Works At Pfizer | Mythdetector.com
  5. Heiko von der Leyen: The Physician Behind Ursula von der Leyen’s Political Ascent
• Heiko von der Leyen sits on the supervisory board of the gene therapy research center in Padua, Italy.

  75%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Reasoning

  • The claim refers to the research center for gene therapy and RNA-based drugs established by the University of Padua, financed through Italy's PNRR with €320 million¹².
  • The University of Padua created a Foundation on 8 June 2022 to manage that gene therapy research line, and Orgenesis (where Heiko von der Leyen is Medical Director) designated him as its representative on the Foundation's Consiglio di sorveglianza (supervisory board)².
  • Orgenesis announced in September 2022 that he was taking on the supervisory board/committee role³, and he was formally appointed to the supervisory board on 30 September 2022⁴.
  • So the substance — that he sat on the supervisory board of the Padua gene therapy research center — is accurate, and multiple independent sources confirm it³²⁵.
  • However, the present tense "sits" is inaccurate: he resigned from that role in October 2022, about a month after being appointed, after Italian media reported on his involvement⁶⁷⁸. The EU transparency commissioner also later found no conflict of interest⁹¹⁰.

  Overall validity: 75%

  (Substantively true — he was appointed to the supervisory board of the Padua gene-therapy/RNA research foundation — but the claim's present tense is misleading, since he resigned in October 2022.)

  1. Terapia genica e tecnologia Rna all'Università di Padova
  2. Padova, il marito di Ursula von der Leyen nel centro di ricerca sui farmaci guidato dall’Ateneo - CorrieredelVeneto.it
  3. The Von Der Leyens & Orgenesis: Deep Investigation
  4. Heiko Echter von der Leyen
  5. Ursula von der Leyen Has a Transparency Problem - https://eutoday.net
  6. Heiko von der Leyen - Wikipedia
  7. Il marito di Ursula von der Leyen lascia il centro di ricerca ...
  8. Debunked: Ursula von der Leyen's husband is not the director of a company owned by Pfizer
  9. EU transparency commissioner: No conflict of interest for Ursula von der Leyen’s husband – POLITICO
  10. It Is False That Ursula Von Der Leyen’s Husband Works At Pfizer | Mythdetector.com
• In 2020, Orgenesis's Italian branch became a partner in a gene therapy research center in Padua, Italy.

  35%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Reasoning:

  • The Padua-based research center in question is the National Center for Gene Therapy and Drugs based on RNA Technology (Centro Nazionale di Ricerca "Sviluppo di terapia genica e farmaci con tecnologia a RNA"), a foundation created by the University of Padua¹².
  • Orgenesis's Italian branch (Orgenesis Italy Srl) is indeed listed among the 49 partner entities of that center, and Orgenesis is described as one of the project's founders³¹.
  • However, the date is wrong. The foundation was established by the University of Padua on 8 June 2022, and its governing bodies were elected on 30 September 2022 — not 2020¹².
  • Orgenesis Italy SRL was itself incorporated in 2022 (and the parent's SEC filing states Orgenesis "has joined an Italian consortium" at that time), so the Italian branch did not exist in 2020⁴⁵.
  • The "2020" appears to stem from a different event: Heiko von der Leyen became Medical Director of Orgenesis in December 2020⁶⁷. He was only appointed to the Padua center's supervisory board in September 2022²⁸¹.
  • So the underlying relationship (Orgenesis's Italian branch is a partner in the Padua gene-therapy center) is accurate, but the stated year — the central element of the claim — is incorrect by two years.

  Overall validity: 35%

  1. Parliamentary question | Potential conflict of interests involving the President of the Commission | E-003717/2022 | European Parliament
  2. Padova, il marito di Ursula von der Leyen nel centro di ricerca sui farmaci guidato dall’Ateneo - CorrieredelVeneto.it
  3. Centro nazionale per lo sviluppo di terapia genica e farmaci con tecnologia a RNA | Università di Padova
  4. description of business
  5. Orgenesis Inc. - 10K - Annual Report - March 22, 2023
  6. Heiko von der Leyen - Wikipedia
  7. Heiko Echter von der Leyen（Medical Director of Orgenesis Biotech Company, USA）_Baiduwiki
  8. Ursula von der Leyen Has a Transparency Problem - https://eutoday.net
• Ursula von der Leyen characterized the connection between her approval of the €320 million grant for the gene therapy research center in Padua and her husband Heiko von der Leyen's supervisory board seat there as a coincidence.

  10%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Reasoning:

  • The claim that Ursula von der Leyen called the Padua link a "coincidence" traces back to viral social media posts (e.g., by accounts such as Mees Wynants) that end with the line "She calls it a coincidence"¹²³.
  • No news report, official statement, interview transcript, or professional fact-check quotes von der Leyen making any such "coincidence" remark. The phrase appears only in the circulating social posts themselves.
  • A debunking analysis of this exact viral narrative states explicitly: "There is also no reliable evidence that Ursula von der Leyen personally selected the project, directed the funding toward her husband or dismissed the controversy as a 'coincidence'"⁴.
  • The documented official response came not from von der Leyen herself but from EU Transparency Commissioner Věra Jourová, who wrote that Heiko von der Leyen "had not been involved in the grant application process and the award," so "a conflict of interest of the President can also be excluded" — a finding of no conflict of interest, not a "coincidence" characterization⁵⁶.
  • Underlying facts are partly real (Heiko von der Leyen was appointed to the supervisory board in Sept 2022 and resigned a month later; the €320M was PNRR/EU recovery funding), but the specific attributed quote about a "coincidence" is unsupported by any reliable source⁶⁴.

  Overall validity: 10%

  1. Instagram
  2. Mees Wynants on X: "Ursula von der Leyen approved €320 million for a centre where her husband sits on the board. She flew to Rome to do it personally. Heiko von der Leyen is medical director at a biotech company that partnered with a gene therapy centre in Padua. That centre took the €320 million,… / X
  3. Instagram
  4. Instagram
  5. Parliamentary question | COVID-19: does the position of Ursula von der Leyen’s husband create a conflict of interest with some of the Commission’s activities? | E-003749/2022 | European Parliament
  6. EU transparency commissioner: No conflict of interest for Ursula von der Leyen’s husband – POLITICO
• The gene therapy research center in Padua, Italy received a €320 million grant from the EU's COVID recovery fund.

  95%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Reasoning

  • The claim refers to Italy's National Center for Gene Therapy and Drugs based on RNA Technologies, a national consortium whose hub is at the University of Padova (Padua)¹.
  • Its funding is €320 million, and this "mostly comes from the EU's 'Next Generation Europe' programme" — the EU's post-pandemic/COVID recovery fund¹.
  • The center clusters 32 research institutes, 16 pharmaceutical companies, and a major Italian bank, and supports roughly 900 permanent scientists plus 400 postdocs/PhD students¹.
  • An Italian ecosystem article likewise describes the network as "backed by more than €320 million in funding from the EU's recovery plan"²³, and the center's own site references "over €320 million in public investment"⁴.
  • Minor imprecision: it is a national center (consortium) with its hub in Padua, not solely a single Padua institute, and the EU recovery money is the majority rather than the sole source. These do not change the substance of the claim.

  The core facts — a gene therapy research center based in Padua, €320 million, funded mainly by the EU's COVID recovery fund (NextGenerationEU) — are all confirmed.

  Overall validity: 95%

  1. Will Italy’s bet on advanced therapies pay off? | Nature Italy
  2. Italy builds national network for gene therapy and rna-based medicines
  3. Italy builds national network for gene therapy and rna-based medicines
  4. The Future Is Now: Italy’s National Center enters a new phase for gene therapies and RNA-based medicines - RNA Genetherapy
• Heiko von der Leyen received a seat on the supervisory board of the gene therapy research center in Padua, Italy, due to Orgenesis's role as a partner in the center.

  90%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Based on the evidence gathered, I can evaluate this claim.

  Reasoning:

  • The claim states that Heiko von der Leyen (husband of European Commission President Ursula von der Leyen) received a seat on the supervisory board of the gene therapy research center in Padua, Italy, because of Orgenesis's role as a partner in the center.
  • Multiple independent sources confirm the core facts:
    • An Italian subsidiary of Orgenesis joined a EU-funded gene and cell therapy project, and Heiko von der Leyen was elected to sit on the project's supervisory board; he later resigned after Italian media coverage¹.
    • Orgenesis was among the organizations involved in the Padua-based research project, and Heiko von der Leyen was appointed to the project's supervisory board in September 2022, resigning the following month².
    • Orgenesis's Italian subsidiary was a partner in this project, and the company announced he would take on the center's supervisory committee role³.
    • He was appointed as a member of the supervisory board of an Italian research institution on September 30, 2022, while serving as Medical Director of Orgenesis⁴.
  • The causal element ("due to Orgenesis's role as a partner") is supported: Orgenesis Inc. itself was involved in the appointment, and the EU transparency commissioner's letter references declarations by "both Orgenesis Inc. and Prof. Dr. von der Leyen" regarding his joining the board¹. The commissioner noted he joined only after the company had been selected to take part¹.

  The factual core of the claim — the seat on the Padua gene therapy center's supervisory board and Orgenesis's role as a partner — is well-corroborated by multiple independent sources.

  Overall validity: 90%

  1. EU transparency commissioner: No conflict of interest for Ursula von der Leyen’s husband – POLITICO
  2. Ursula von der Leyen Has a Transparency Problem - https://eutoday.net
  3. The Von Der Leyens & Orgenesis: Deep Investigation
  4. Heiko Echter von der Leyen（Medical Director of Orgenesis Biotech Company, USA）_Baiduwiki
• Angela Merkel appointed Ursula von der Leyen to a position at the European Commission.

  15%

  Model: DeepSeek V4.1 Flash Checked on: 08/10/2026

  Analysis of the claim:

  • Ursula von der Leyen was proposed by the European Council (the collective body of EU heads of state and government) as its candidate for President of the European Commission on 2 July 2019, and then elected by the European Parliament on 16 July 2019 with 383 votes¹²³.
  • She took office as Commission President on 1 December 2019³¹.
  • Angela Merkel was only one member of the European Council; the nomination was a collective decision of EU leaders, not a personal appointment by Merkel¹².
  • Notably, Germany actually abstained in the European Council's nomination vote (though Merkel personally backed her)¹⁴.
  • Merkel did appoint von der Leyen to German federal cabinet posts (Family Affairs, Labour, Defence) — but those are national government roles, not positions at the European Commission¹⁵.
  • So while Merkel was a key supporter and party ally, she did not "appoint" von der Leyen to the European Commission; that role resulted from a European Council nomination and a European Parliament election⁶⁴³.

  Conclusion: The claim conflates Merkel's appointments of von der Leyen to the German cabinet with the EU Commission presidency. The Commission post was not Merkel's to appoint — it was proposed by the European Council collectively and confirmed by the European Parliament. There is a kernel of truth (Merkel backed her and was part of the nominating body), but as stated the claim is largely inaccurate.

  Overall validity: 15%

  1. Ursula von der Leyen
  2. Ursula von der Leyen - Geschichte der CDU - Konrad-Adenauer-Stiftung
  3. Parliament elects Ursula von der Leyen as first female Commission President | News | European Parliament
  4. Germany's Ursula von der Leyen nominated to lead EU Commission
  5. Ursula von der Leyen | Boston Global Forum
  6. Ursula von der Leyen is now president of the European Commission. - The Washington Post